{"url_path":"/sec/eton/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1710340/0001437749-26-017064-index.html","accession_number":"0001437749-26-017064","cik":"0001710340","ticker":"ETON","issuer_name":"Eton Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1710340/0001437749-26-017064-index.html","primary_entity_key":"0001710340","primary_entity_name":"Eton Pharmaceuticals, Inc."},"word_count":47,"has_tables":true,"body_markdown":"**Item 5. Other Information**\n\n \n\n*Rule 10b-5(1) Trading Plans.* During the *three*-month period ended *March 31, 2026*, no director or officer of the Company adopted or terminated a “Rule *10b5*-*1* trading arrangement” or “non-Rule *10b5*-*1* trading arrangement,” as each term is defined in Item *408*(a) of Regulation S-K."}